UK Markets closed
  • NIKKEI 225

    27,581.66
    -388.56 (-1.39%)
     
  • HANG SENG

    25,473.88
    +387.45 (+1.54%)
     
  • CRUDE OIL

    72.37
    +0.72 (+1.00%)
     
  • GOLD FUTURES

    1,806.00
    +6.20 (+0.34%)
     
  • DOW

    34,930.93
    -127.59 (-0.36%)
     
  • BTC-GBP

    28,731.03
    +1,044.92 (+3.77%)
     
  • CMC Crypto 200

    938.33
    +8.40 (+0.90%)
     
  • Nasdaq

    14,762.58
    +102.01 (+0.70%)
     
  • ^FTAS

    4,024.08
    +13.79 (+0.34%)
     

Global Precision Medicine Software Market to Reach $2.6 Billion by 2027

·25-min read

Abstract: - Global Precision Medicine Software Market to Reach $2. 6 Billion by 2027. - Amid the COVID-19 crisis, the global market for Precision Medicine Software estimated at US$1.

New York, July 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Software Industry" - https://www.reportlinker.com/p06032637/?utm_source=GNW
3 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at aCAGR of 10.1% over the period 2020-2027. On-Premise, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cloud segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $352.1 Million, While China is Forecast to Grow at 13.4% CAGR
- The Precision Medicine Software market in the U.S. is estimated at US$352.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$537.8 Million by the year 2027 trailing a CAGR of 13.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 8.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

- Select Competitors (Total 34 Featured) -

  • 2bprecise, LLC

  • Fabric Genomics, Inc.

  • Foundation Medicine, Inc.

  • Gene42, Inc.

  • Human Longevity, Inc.

  • Lifeomic Health, LLC

  • N-Of-One, Inc. (A Subsidiary of Qiagen N.V.)

  • Pieriandx, Inc.

  • Sophia Genetics Sa

  • Sunquest Information Systems, Inc.

  • Syapse, Inc.

  • Translational Software Inc.




Read the full report: https://www.reportlinker.com/p06032637/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Precision Medicine
Software by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Precision Medicine Software
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Precision Medicine
Software by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for On-Premise by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for On-Premise by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for On-Premise by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Cloud by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Cloud by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Cloud by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Healthcare
Providers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Healthcare Providers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Healthcare Providers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Research Centers &
Academic Institutes by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Research Centers & Academic
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Research Centers &
Academic Institutes by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 19: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Pharma & Biotech
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 22: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Pharmacogenomics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Pharmacogenomics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Pharmacogenomics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Rare Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Rare Diseases by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Rare Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Precision Medicine
Software by Deployment - On-Premise and Cloud - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 35: USA Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 36: USA 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: USA Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 51: Canada 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 54: Japan 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 63: China 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Precision
Medicine Software by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Precision Medicine
Software by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 72: Europe 15-Year Perspective for Precision Medicine
Software by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Europe Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 81: Europe 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 90: France 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 98: Germany Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 99: Germany 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 107: Italy Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 108: Italy 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 109: UK Current & Future Analysis for Precision Medicine
Software by Deployment - On-Premise and Cloud - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 110: UK Historic Review for Precision Medicine Software
by Deployment - On-Premise and Cloud Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 111: UK 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Precision Medicine Software
by End-Use - Other End-Uses, Healthcare Providers, Research
Centers & Academic Institutes and Pharma & Biotech Companies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 116: UK Historic Review for Precision Medicine Software
by Application - Oncology, Pharmacogenomics, Rare Diseases and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Precision Medicine
Software by Deployment - On-Premise and Cloud Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 120: Spain 15-Year Perspective for Precision Medicine
Software by Deployment - Percentage Breakdown of Value Sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Table 121: Spain Current & Future Analysis for Precision
Medicine Software by End-Use - Other End-Uses, Healthcare
Providers, Research Centers & Academic Institutes and Pharma &
Biotech Companies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Precision Medicine
Software by End-Use - Other End-Uses, Healthcare Providers,
Research Centers & Academic Institutes and Pharma & Biotech
Companies Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Precision Medicine
Software by End-Use - Percentage Breakdown of Value Sales for
Other End-Uses, Healthcare Providers, Research Centers &
Academic Institutes and Pharma & Biotech Companies for the
Years 2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Precision
Medicine Software by Application - Oncology, Pharmacogenomics,
Rare Diseases and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 125: Spain Historic Review for Precision Medicine
Software by Application - Oncology, Pharmacogenomics, Rare
Diseases and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 126: Spain 15-Year Perspective for Precision Medicine
Software by Application - Percentage Breakdown of Value Sales
for Oncology, Pharmacogenomics, Rare Diseases and Other
Applications for the Years 2012, 2020 & 2027

RUSSIA
Table 127: Russia Current & Future Analysis for Precision
Medicine Software by Deployment - On-Premise and Cloud -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032637/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting